anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
This study was to explore the role of ELOVL6 in the development of head and neck squamous cell carcinoma (HNSCC). Considering its previously identified oncogenic role in hepatocellular carcinoma. ELOVL6 gene expression, clinicopathological analysis, enrichment analysis, and immune infiltration analysis were based on the data from Gene Expression Omnibus and The Cancer Genome Atlas, with additional bioinformatics analyses performed. Human HNSCC tissue microarray and cell lines were used. The expression of ELOVL6 in HNSCC was detected by quantitative polymerase chain reaction, immunohistochemistry assay, and western blot analysis. The proliferation ability of HNSCC cells, invasion, and apoptosis were evaluated using cell counting kit-8 method, Transwell assay, and flow cytometry, respectively. Based on the data derived from the cancer databases and our HNSCC cell and tissue studies, we found that ELOVL6 was overexpressed in HNSCC. Moreover, ELOVL6 expression level had a positive correlation with clinicopathology of HNSCC. Gene set enrichment analysis showed that ELOVL6 affected the occurrence of HNSCC through WNT signaling pathway. Functional experiments demonstrated that ELOVL6 knockdown inhibited the proliferation and invasion of HNSCC cells while promoting apoptosis. Additionally, compound 3f, an agonist of WNT/β-catenin signaling pathway, enhances the effect of ELOVL6 on the progression of HNSCC cells. ELOVL6 is upregulated in HNSCC and promotes the development of HNSCC cells by inducing WNT/β-catenin signaling pathway. ELOVL6 stands a potential target for the treatment of HNSCC and a prognosis indicator of human HNSCC.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a stable pharmaceutical composition designated for oral administration. The composition comprises amlodipine benzylate in amount from 3.0 to 20 mg and atenolol in amount from 25.0 to 125 mg in combination with pharmaceutically compatible excipients. Diluting agents are taken among a group comprising directly pressable lactose, anhydrous lactose, microcrystalline cellulose, gelatinized starch, calcium dihydrogen phosphate or its modified form. Raising agents are taken among a group comprising starch, modified starch, croscarmelose sodium. Binding agents are taken among a group comprising starch, polyvinylpyrrolidone and cellulose derivatives. Agents providing slipping property are taken among a group comprising magnesium stearate, talc and colloidal silicon dioxide. Invention describes also 5 variants of a method of preparing a pharmaceutical composition. The composition shows good physical and chemical stability because of thoroughly selected pharmaceutical excipients that are compatible with two active medicinal components simultaneously. EFFECT: improved properties of preparation. 16 cl, 14 ex
Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
After 2 cycles of induction chemotherapy, patients with favorable response undergo standard-dose (70Gy) intensity modulated radiotherapy (IMRT) 5 days per week for approximately 7 weeks (33 fractions). Patients also receive concurrent cisplatin once every three weeks for 3 cycles.
Method and apparatus for producing a broad-spectrum therapeutic for inactivating multiple coronavirus strains including COVID-19. The present invention generates an in situ light source which can inactivate the coronavirus within the body without damaging host cells. This invention couples chemiluminescence-generating compounds with various light-sensitive anti-viral compounds. When activated by chemiluminescence-generated light, the anti-viral compounds inactivate nearby virus particles. In one aspect, the coupled components are co-encapsulated in polymer nanospheres for oral and intranasal delivery. In another aspect of the invention, the coupled components are co-encapsulated in phospholipid nanosomes for intravenous delivery.
Pre-exposure prophylaxis (PrEP) uptake has been slow among young men who have sex with men (YMSM), particularly those of color who experience a high rate of new HIV infections in the United States. Limited PrEP knowledge, unfamiliarity with how to access PrEP, medical mistrust, and stigma are barriers to PrEP care engagement among YMSM, including those of color. Peer-driven social network interventions that train individuals as peer educators to disseminate information about HIV prevention and treatment within their social networks have been implemented to address similar barriers and improve HIV outcomes within hard to reach populations. YMSM of color engaged in HIV/PrEP care often employ resilience processes to overcome socio-structural barriers to HIV prevention and care. As such, training YMSM of color engaged in HIV/PrEP care as peer PrEP educators may position them as credible sources of PrEP information who can influence behavior change (i.e., PrEP care engagement) among YMSM peers of color in their social networks via their ability to disseminate culturally competent PrEP messages in the context of their personal experiences using these resilience processes to navigate the healthcare system, medical mistrust, and stigma. Drawing on existing peer-driven social network interventions, the diffusion of innovations and information-motivation-behavioral skills models, and Harper et al.'s resilience framework, this study will develop and pilot Onboarding Positives and PrEP users to Engage Negatives (OPPEN), a peer-driven PrEP education social network intervention, among YMSM of color in San Diego, California. Through three small-group and two one-on-one sessions, OPPEN will train YMSM of color engaged in HIV/PrEP care to be peer PrEP educators within their social networks. In Phase I, OPPEN was developed, pretested, and refined using an iterative process that integrated feedback elicited from YMSM of color living with HIV and YMSM using PrEP trained via OPPEN as well as HIV-negative YMSM who could benefit from PrEP (AIM 1). In Phase II, OPPEN will be piloted in a randomized controlled trial with 70 YMSM of color engaged in HIV/PrEP care (i.e., indexes; 50% HIV-positive) randomly assigned to OPPEN (n=35) or a time- and attention-matched control condition (n=35). All indexes will receive coupons to recruit YMSM peers of color within their social networks to the study. Assuming \~2 peers will be recruited per index, \~140 peers will present at the study site (i.e., peer-recruits) and undergo HIV testing. HIV-negative peer-recruits interested in PrEP will be scheduled for a PrEP clinic visit. Data collected via surveys (baseline and 3-month study visits) and medical records will be used to evaluate the preliminary effect of OPPEN on PrEP interest, linkage, and uptake among peer-recruits (AIM 2) and theory-based mechanisms targeted by OPPEN among indexes and peer-recruits (AIM 3). OPPEN acceptability and feasibility will be evaluated using a mixed-methods approach (AIM 4).
Atopic dermatitis (AD) is a common inflammatory skin disease with multiple clinical manifestations. Among AD phenotypes, psoriasiform AD shows the coexistence of eczematous itching lesions in flexural areas with psoriasiform plaques. The use of anti-interleukin (IL)-4 and anti-IL-13 in psoriasiform AD may lead to therapeutic failure or worsening of manifestations. A recent Delphi consensus proposed Janus kinase inhibitors (JAKi) as a viable alternative, even as a first-line treatment, in patients with different clinical phenotypes of AD, including psoriasiform AD. We performed a retrospective analysis of patients in our dermatology clinic with moderate-to-severe AD who were treated with JAKi. Among 192 patients overall, 21 had psoriasiform AD. We used the Eczema Area and Severity Index (EASI), Pruritus-Numerical Rating Scale and Dermatology Life Quality Index for considering severity scores, and reduction was observed in all 21 patients at week (W) 4, W16 and W24 of treatment. At W16, 81% and 67% achieved EASI-75 and EASI-90, respectively, while at W24 95% of patients achieved EASI-75 and 86% obtained EASI-90. No adverse event led to treatment interruption. This study confirmed the clinical effectiveness of JAKi treatment in adult patients with moderate-to-severe psoriasiform AD, with a good safety profile. These drugs are proposed as the first choice for treating this form of AD, although further studies with larger cohorts are required.
After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-marketing. Symptoms included exertional dyspnea, cough, chest pain, and fever. X-rays showed interstitial or alveolo-interstitial changes, and pulmonary function tests revealed a restrictive pattern with decreased DLco. Most cases occurred within the first 3 months of treatment with Nilutamide Tablets, and most reversed with discontinuation of therapy. A routine chest X-ray should be performed prior to initiating treatment with Nilutamide Tablets. Baseline pulmonary function tests may be considered. Patients should be instructed to report any new or worsening shortness of breath that they experience while on Nilutamide Tablets. If symptoms occur, Nilutamide Tablets should be immediately discontinued until it can be determined if the symptoms are drug related.

Hepatitis

Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of Nilutamide Tablets. Hepatotoxicity in these reports generally occurred within the first 3 to 4 months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in 1% of Nilutamide Tablet patients in controlled clinical trials. 

Serum transaminase levels should be measured prior to starting treatment with Nilutamide Tablets, at regular intervals for the first 4 months of treatment, and periodically thereafter. Liver function tests should also be obtained at the first sign or symptom suggestive of liver dysfunction, e.g. nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, jaundice, or right upper quadrant tenderness. If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, Nilutamide Tablets should be immediately discontinued with close follow-up of liver function tests until resolution.

Use in Women

Nilutamide Tablets have no indication for women, and should not be used in this population, particularly for non-serious or non-life threatening conditions.

Other

Foreign post-marketing surveillance has revealed isolated cases of aplastic anemia in which a causal relationship with Nilutamide Tablets could not be ascertained.
1422855 Implantable prosthesetic tissue: surgical drains CESKOSLOVENSKA AKADEMIE VED 7 Aug 1973 [15 Feb 1973] 37429/ 73 Heading ASR [Also in Division C3] In Example 1 a spongey implantable prosthesis which allows growth of tissue through the pores thereof is prepared by mixing a nitric acid solution of a hydrophilic polymer (see Division C3) with urea nitrate crystals. The mixture may be shaped in a 1:5 mm gap between a concave matrix and a convex patrix to provide a spherical cap for covering a denuded joint of inner radius 15 mm and sagittal depth 32 mm with a thickened edge, removing the patrix, coagulating the shaped material by immersion in water, removing the matrix and washing the shaped article in lukewarm water to extract the urea mononitrate and finally sterilizing the resulting cellular material by boiling in physiological solution. In Example 3 a similar mixture is used for a mammary prosthesis: In Example 4 a similar starting mixture is rolled into a sheet, washed and coagulated in water to form an elastic spongeous plate, cut to size, soaked in an antibiotic, cancerostatic or cytostatic drug, further dipped in the original homogeneous starting polymer solution and subsequently treated with sterile water to develop a thin hydrogel layer on the surface which is capable of allowing controlled difusion of the incorporated drug. The result is a material useful as a temporary body implant which swells and releases the drug after implantation. As alternatives the implant material may be sealed in a sterile polypropylene capsule or may be dried and sterilized with ionizing radiation for subsequent application in the dried state. In Example 6 a polymer solution as in Example 1 is extruded into 2 mm sticks of 25 cm length coated with homogeneous starting copolymer solution and subsequently coagulated and rendered porous by washing with water and sterilizing in boiling water. Both ends of each stick are cut off to expose the porous core and to provide a material suitable for draining a superfluous cerrebo-spinal humour from intracranium to vend cava in hydrocephalic patients.
FIELD: medicine. SUBSTANCE: method involves administering traditional therapy and plasmapheresis and ultrasonic blood irradiation therapy with physiological salt solution of sodium chloride in the amount of 300-400 ml being infused with Sybasone in the amount of 0.2 mg/kg of body weight and Dimedrol in the amount of 0.2 mg/kg of body weight being added. The session is carried out in two stages. 300-400 ml of blood is taken at the first stage. It is centrifuged at 1600 rpm during 15 min. Plasma compensation is carried out depending on initial hematocrit reading, general protein and blood platelets contents in patient blood. General protein contents being from 60 to 80 g/l, blood platelets from 150 to 250 g/l, hematocrit reading being from 32 to 36%, plasma compensation is carried out with physiological salt solution of sodium chloride in the amount equal to 2-fold value of removed plasma. General protein contents being from 60 to 80 g/l, blood platelets from 150 to 250 g/l, hematocrit reading being greater than 36%, plasma compensation is carried out with colloid solution and physiological salt solution of sodium chloride in 2:1 proportion in the general amount equal to 2-fold value of removed plasma. General protein contents being less than 60 g/l, blood platelets less than 150 g/l, hematocrit reading being from 32 to 36%, plasma compensation is carried out with fresh frosted plasma of the same group in the amount of one volume of removed plasma and physiological salt solution of sodium chloride in the amount equal to 2-fold value of removed plasma. General protein contents being less than 60 g/l, blood platelets less than 150 g/l, hematocrit reading being greater than 36%, plasma compensation is carried out with fresh frosted plasma of the same group in the amount of one volume of removed plasma and colloid solution of rheopolyglycine or rheomacordex or rheogluman in the amount equal to the volume of removed plasma. Formed blood elements concurrently treated with ultrasonic radiation are reinfused at the second stage. EFFECT: enhanced effectiveness of treatment. 4 cl, 2 tbl
Forward head posture (FHP) is nowadays the most common postural problem. In FHP, the head protrudes forward from the sagittal plane and appears to be positioned in front of the body, and this condition is considered the most common postural deformity. The prevalence of anterior head translation in neck pain patients was found to be 37%, out of which 58% were females and 42%were males. FHP is among the most common abnormal postures in upper quarter. 85% of patients with myofascial pain syndrome have FHP. Even more alarming is how frequently these problems are seen in younger populations since it's suggested that problems at a young age may lead to more serious consequences later in life. Pilate's method is a physical fitness system that was developed during the First World War in the early 20th century by Joseph Hubertus Pilates. Direction Control and Range Control exercises are two key types of specific exercises that should be used when specific uncontrolled movements are found. Pilates is a mind-body exercise that focuses on strength, core stability, flexibility, muscle control, posture and breathing. Exercises can be mat-based or involve use of specialized equipment. Six major components of Pilates as: Centering, Concentration, Control, Precision, Flow and Breathing.

pilates exercise and postural correction play a major role in restoring the normal posture in patients with forward head posture so this trial will be conducted to investigate efficacy of adding Pilates to postural correction exercise on nerve root function and electromyography activity in symptomatic forward head posture.
A system and method for ordering, delivering and billing of the medical equipment utilizing the electronic data flow management system is disclosed. The system comprises at least one healthcare provider having at least one workstation, a computer ordering server, an online database and at least one durable medical equipment (DME) company having a mainframe server. The workstation generates and sends an order for the medical equipment. The computer ordering server receives the order from the workstation. The online database receives and stores the order from the computer ordering server. The mainframe server receives the order from the online database and delivers the medical equipment to a patient. The DME company utilizes a billing module to generate a bill for the medical equipment. The electronic data flow management system provides a secure and cost effective way of procuring the medical equipment to the healthcare provider.
In an 8-week randomized double-blind placebo-controlled outpatient pilot trial the efficacy of gabapentin in the treatment of alcohol dependence will be studied in 60 patients. Participants will be randomly assigned to treatment under double-blind conditions with either 1) a fixed dosing schedule of gabapentin or 2) placebo. All participants will receive weekly supportive behavioral treatment that promotes abstinence from alcohol and other substances, encourages mutual-support meeting attendance, and facilitates compliance with study medication. The primary outcome measures will be: the reduction of heavy drinking days per week as measured by the timeline follow-back method.

Participants will be alcohol-dependent men and nonpregnant women who report drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days. The daily minimum drinking requirements are consistent with the commonly accepted definition of "binge drinking." A minimum requirement of having a heavy drinking episode 4 days a week would select for a population of individuals who are drinking excessively more days than not. A minimum threshold of weekly alcohol use is set to prevent a "floor effect" (i.e. participants with minimal alcohol use at baseline would be unable to demonstrate significant improvement.)
PURPOSE:To obtain the titled substance having a high endotoxin specificity, by subjecting amebocyte lysate of a horseshoe crab or a liquid containing the same to a specific liquid chromatography, and removing impurities. CONSTITUTION:Amebocyte lysate of a horseshoe crab, e.g. Limulus polyphemus or Tachypleus tridentatus or a liquid containing the same is subjected to the adsorptive liquid chromatography with a polysaccharide sulfate, e.g. dextran sulfate agarose, agarose sulfate, etc. as an adsorbent carrier. In the process, a fraction containing an activating factor for nonendotoxic coagulable enzyme precursor, e.g. beta-1,3-glucan, is removed from the adsorbent carrier with a salt solution having 0.15-0.3 ionic strength, preferably a tris(hydroxymethyl)aminomethane-hydrochloric acid (tris-hydrochloric acid) buffer solution containing NaCl, to give the aimed amebocyte lysate having a high specificity for endotoxin or a liquid containing the same.
With With the increased number of participants in sports and leisure time activities, the incidence of ankle ligament injuries has been correspondingly increased. Various surgical methods have been reported for chronic ankle instability. Of these methods, the modified Brostrom procedure is currently used most frequently, and its excellent treatment outcomes have been reported. If there are any methods for obtaining a strong ligament fixation force which are both technically simple and safe, such methods would shorten the operative time and be helpful for surgeons with little experience in managing chronic ankle instability to obtain excellent treatment outcomes. In recent years, a procedure using a suture anchor, which is used for various types of ligament or tendon reconstructions, has been frequently performed. To date, however, few studies have reported clinical outcomes of suture anchor techniques and comparisons of clinical results between suture anchor techniques and other procedures. Given the above background, we prospectively compared the clinical outcomes between the bone tunnel and suture anchor techniques in the modified Brostrom procedure for chronic lateral ankle instability.